-
-
-
-
-
-
-
Halozyme Therapeutics (HALO) PT Raised to $90 at Benchmark Following Strong Q4 Results
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Halozyme Therapeutics (HALO)
-
-
-
-
-
-
-
HALOZYME REPORTS FULL YEAR 2024 RECORD REVENUE OF $1.015 BILLION AND EXCEEDS ITS FINANCIAL GUIDANCE FOR ROYALTY REVENUE, ADJUSTED EBITDA AND NON-GAAP DILUTED EPS
-
-
-
-
-
-
-
Halozyme Provides Update on Non-Binding Proposal to Combine with Evotec
-
-
-
-
-
-
-
HALOZYME REPORTS FIRST QUARTER 2024 FINANCIAL AND OPERATING RESULTS
-
-
-
-
-
-
-
HALOZYME REPORTS THIRD QUARTER 2022 FINANCIAL AND OPERATING RESULTS
-
-
-
-
-
-
-
UPDATE: SVB Leerink Assumes Halozyme Therapeutics (HALO) at Outperform, 'Durability Underappreciated for This Partner of Choice'
-
1,177,135 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

